CareTrust REIT, Inc. (CTRE) — closed signal from December 29, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 29, 2026.
Predicted vs. what happened
What happened
Reached its target in 45 days.
The thesis — published December 29, 2025
This is a steadier real estate income stock for healthcare properties. It tends to move less than high-flying names and pays a dividend, so it can provide income while markets are weak. Recent analyst work says its intrinsic value is higher than the market price, so buyers may slowly step in when the price softens. Expect modest upside plus dividend income over 0-3 months; not a fast momentum trade.
Primary drivers
- Analyst value work could make the stock get higher over time
- Healthcare rents create steady cash paid to the company
- Dividends add to investor returns when markets fall
- Lower price swings provide balance against volatile sectors
How it played out
CTRE: target reached in 45 days
Lyra published CTRE at $36.45 on 2025-12-29. The thesis expected 10% growth over a short window, with modest upside plus dividend income rather than a fast momentum trade. The thesis pointed to analyst value work, healthcare rents, dividends, and lower price swings as the main drivers.
Inside the window, CTRE reached the $39.73 target in 45 days. It peaked at $41.72 on 2026-02-27, with a 14.5% peak gain. It ended the window at $37.13. The thesis played out: the target was reached, and the move went beyond it before giving back part of the gain.
What happened during the window
On February 6, Investor's Business Daily reported that CTRE's Relative Strength Rating rose to 83 and that the stock was above a 38.32 flat-base entry. On March 16, Barron's reported that CareTrust had raised its quarterly dividend to $0.39 per share and had reported adjusted funds from operation of $0.47 per share earlier that month.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.